Efficacy of Pentoxifylline in Managing Oral Submucous Fibrosis: A Systematic Review and Network Analysis
Medical Sciences · 2026-11-07 · 14 (7) · 761
DOI: 10.3390/medsci14070761 ↗Abstract
Background: Oral submucous fibrosis (OSMF) is a potentially malignant disorder characterized by debilitating symptoms, including a burning sensation and reduced mouth opening. Although various therapeutic options exist, no consensus exists on the most effective management strategy. This systematic review assesses the efficacy of pentoxifylline over other medical management options for OSMF. Methods: This review was performed in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. We conducted a systematic search of PubMed, Scopus, Cochrane Library, Embase, and Google Scholar for articles published from 2000 up to February 2026. We included studies that compared the efficacy of pentoxifylline with other medical management techniques in OSMF patients. We assessed outcomes including maximal mouth opening, burning sensation, tongue protrusion, and cheek flexibility, and secondary outcomes such as adverse effects of pentoxifylline were recorded. We assessed the risk of bias using the Cochrane Collaboration tool (RoB2) for randomized controlled trials. Results: This review included 14 studies. The available data do not show statistically significant efficacy of pentoxifylline compared with corticosteroids, hyaluronidase, spirulina, multivitamins, or antioxidants. Pentoxifylline has some mild, dose-dependent side effects reported, such as gastritis, dyspepsia, vomiting, anxiety, and tremor. Conclusions: The evidence in this review does not conclude a statistically significant advantage of pentoxifylline over other medical treatments for MMO, BS, or TP in OSMF. All comparisons were imprecise and certainty ranged from low to very low.
EUVIMED